

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

WEDNESDAY, JUNE 12, 2024

AGENDA

5:00 pm **IN-PERSON: Check-In, Visit Exhibits and Reception (dinner to follow)**

5:45 pm **VIRTUAL: Log-In to Virtual Conference**

5:55 pm **Educational Meeting Begins - Welcome and Introductions**

[Catherine E. Lai, MD, MPH](#) | Hematology Oncology | Activity Co-Director

[Ryan C. Massa, MD](#) | Hematology Oncology | Activity Co-Director

6:00 pm **KEYNOTE: Updates on Palliative and Supportive Care**

[Ramy Sedhom, MD](#) | Hematology Oncology

6:20 pm **Update on Hematologic Malignancies**

Leukemia: [Keith W. Pratz, MD](#) | Hematology Oncology

Lymphoma: [Michael R. Cook, MD](#) | Hematology Oncology

Multiple Myeloma: [Shivani Kapur, MD](#) | Hematology Oncology

7:05 pm **Update on Melanoma**

[Tara C. Mitchell, MD](#) | Hematology Oncology

7:20 pm **Update on Brain Tumors**

[Stephen J. Bagley, MD, MSCE](#) | Hematology Oncology

7:35 pm **Therapeutic Advances in GU Malignancies**

[Samuel U. Takvorian, MD, MS](#) | Hematology Oncology

7:50 pm **Annual Meetings: Breast Cancer Summary**

[Amy S. Clark, MD, MSCE](#) | Hematology Oncology



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

8:05 pm Recent Advances in Management of Lung Cancer

[Christopher A. D'Avella, MD](#) | Hematology Oncology

8:20 pm Recent Advances in Gastrointestinal Cancers

[Ryan C. Massa, MD](#) | Hematology Oncology

8:35 pm Roundtable Q & A, Hot Topics, and Late Breaking News

MODERATORS:

[Corey J. Langer, MD](#) | Hematology Oncology

[Edward A. Stadtmauer, MD](#) | Hematology Oncology

ROUNDTABLE:

[Stephen J. Bagley, MD, MSCE](#)

[Nicholas A. Beam, CRNP](#)

[Amy S. Clark, MD, MSCE](#)

[Michael R. Cook, MD](#)

[Christopher A. D'Avella, MD](#)

[Alfred L. Garfall, MD, MS](#)

[Shivani Kapur, MD](#)

[John A. Kosteva, MD](#)

[Catherine E. Lai, MD, MPH](#)

[Ryan C. Massa, MD](#)

[Tara C. Mitchell, MD](#)

[Keith W. Pratz, MD](#)

[Ramy Sedhom, MD](#)

[Samuel U. Takvorian, MD, MS](#)

9:15 pm Conference Adjourns

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Post Conference Details

After the conference has concluded, all attendees will receive an email from Penn CME with instructions on how to complete the post-test, evaluation, claim credit and obtain a certificate. Look for the email after Wednesday, June 19.

If you missed the Pre-Test, you will still be eligible to obtain your certificate after you complete the Post-Test and Evaluation. A Certificate of Participation is available to attendees who are not physicians or nurses.

Meeting Videos

Website: PennMedicine.org/Abramson/Onc2024

**Recordings from the meeting will be available Tuesday, June 18, 2024 through June 2025*

Overview

This activity is designed to efficiently discuss the most recent clinical advances in oncology. The meeting will address the questions that have emerged from the latest data presented at major international annual meetings. Activity format will provide the opportunity for interaction with Penn Medicine faculty and other attendees. Participants will gain up-to-date, practical information with immediate clinical application, as well as a technical and scientific background on the current state of the field and emerging advances.

Learning Objectives

Upon completion of this activity, participants should be able to:

- Identify recent advances in immunotherapy for cancer treatment
- Implement new clinical findings to a broad range of tumor types
- Identify issues related to extent of therapy by genomics, stage, and patient condition

Who Should Attend

This activity has been designed for medical, surgical, and radiation oncologists, hematologists/oncologists, hematology/oncology fellows, radiologists, neuro-oncologists, thoracic surgeons, urologists, gastroenterologists, pulmonologists, dermatologists, oncology nurses, and other healthcare professionals involved in the treatment of patients with cancer.

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Accreditation



In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

PHYSICIANS: Penn Medicine designates this live activity for a maximum of **3.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: The program awards **3.25 NCPD** hours.

PHYSICIAN ASSISTANTS: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Pas may receive a maximum of **3.25** Category 1 credits for completing this activity.

Penn Medicine Speakers

Activity Co-Directors

Catherine E. Lai, MD, MPH

Associate Professor of Medicine (Hematology Oncology)
Physician Leader, Leukemia Clinical Research Unit
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Ryan C. Massa, MD

Assistant Professor of Clinical Medicine
(Hematology Oncology / Hematology Oncology)
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, US

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Faculty

Stephen J. Bagley, MD, MSCE

Assistant Professor of Medicine (Hematology Oncology)

Assistant Professor of Neurosurgery

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Nicholas A. Beam, CRNP*

Nurse Practitioner (Medical Oncology)

Penn Medicine

Philadelphia, PA, USA

Amy S. Clark, MD, MSCE

Assistant Professor of Medicine (Hematology Oncology)

Physician Lead, Breast Cancer Clinical Research Unit

Vice Chair, Clinical Trial Research and Monitoring Committee 2

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Michael R. Cook, MD

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Christopher A. D'Avella, MD

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Alfred L. Garfall, MD, MS

Associate Professor of Medicine (Hematology Oncology)

Director, Autologous Hematopoietic Stem Cell Transplantation

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

*Nurse Planner**

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Shivani Kapur, MD

Assistant Professor of Medicine (Hematology Oncology)
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

John Kosteva, MD

Associate Professor of Medicine (Hematology Oncology)
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Corey J. Langer, MD

Professor of Medicine (Hematology Oncology)
Director, Thoracic Oncology
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Tara C. Mitchell, MD

Associate Professor of Medicine (Hematology Oncology)
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Keith W. Pratz, MD

Associate Professor of Medicine (Hematology Oncology)
Director, Leukemia Program
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Ramy Sedhom, MD

Assistant Professor of Medicine (Hematology Oncology)
Clinical Director, Palliative Care
Penn Medicine Princeton Health
Co-Lead, Geriatric Oncology
Penn Cancer Service Line
Faculty, Penn Center for Cancer Care Innovation
Perelman School of Medicine at University of Pennsylvania / Penn Medicine
Plainsboro, NJ, USA



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Edward A. Stadtmauer, MD

Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor
Chief, Hematologic Malignancies Section
Division of Hematology Oncology
Co-Leader, Hematologic Malignancies Research Program
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Samuel U. Takvorian, MD, MS

Assistant Professor of Medicine (Hematology Oncology)
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine
Philadelphia, PA, USA

Disclosure of Financial Relationships

Staff in the Office of Continuing Medical and Interprofessional Education (CMIE) (Bruce Brod, MD, MCHI, FAAD, Vaughn Wurst and Belinda Rose, CHCP), and the listed Planning Committee Members (Nicholas A. Beam, CRNP, Barbara Lopez, Hyacen Putmon) have reported that they have no financial relationships with any ineligible companies related to the content of this educational activity.

Financial Relationships

Financial relationships are defined as any relationship, in any amount, with an ineligible company. An ineligible company is defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

The following faculty and planning committee (*) members have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity.

Nicholas A. Beam, CRNP*
Christopher A. D'Avella, MD

Shivani Kapur, MD
John Kosteva, MD

Ryan Massa, MD*
Ramy Sedhom, MD



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

The following planning committee (*) and faculty members have reported the listed financial relationships with ineligible companies related to the content of their presentations. All financial relationships have been mitigated.

FACULTY NAME

Stephen J. Bagley, MD, MSCE

Amy Clark, MD, MSCE

Michael R. Cook, MD

DISCLOSURE(S)

Grant or research support-Incyte Corporation | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kiyatec (Relationship has ended) | Grant or research support-Kite Pharma | Grant or research support-Eli Lilly (Relationship has ended) | Grant or research support-Novocure (Relationship has ended) | Grant or research support-Glaxo Smith Kline (Relationship has ended) | Grant or research support-C2i Genomics | Grant or research support-Tempus | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Telix (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Servier (Relationship has ended)

Grant or research support-Eli Lilly | Grant or research support-Novartis / Amgen (Relationship has ended) | Honoraria-GE Healthcare (Relationship has ended)

Honoraria-Curio Science, A Vaniyam Group Company



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Alfred L. Garfall, MD, MS

Consulting Fee-Janssen Pharmaceuticals (J&J) | Consulting Fee-Amgen (Relationship has ended) | Grant or research support-Novartis (Advanced Health Media) | Grant or research support-Janssen Pharmaceuticals (J&J) | Grant or research support-tmunity (Relationship has ended) | Grant or research support-crispr therapeutics | Consulting Fee-Bristol-Myers Squibb (Relationship has ended) | Consulting Fee-Glaxo Smith Kline (Relationship has ended) | Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended) | Consulting Fee-AbbVie, Inc. (Relationship has ended) | Consulting Fee-Gracell | Consulting Fee-Smart Immune (Relationship has ended)

Catherine Lai, MD, MPH*

Advisor-Genentech | Advisor-Rigel | Advisor-Taiho Oncology (Relationship has ended) | Advisor-AbbVie, Inc. | Advisor-Novartis (Relationship has ended) | Consulting Fee-Jazz Pharma (Relationship has ended) | Advisor-Pfizer, Inc. (Relationship has ended) | Consulting Fee-PDS Biotechnology | Consulting Fee-MacroGenics (Relationship has ended) | Consulting Fee-Astellas (Relationship has ended) | Speakers Bureau-Jazz Pharma (Relationship has ended) | Speakers Bureau-Astellas (Relationship has ended) | Honoraria-OncoLive (Relationship has ended) | Honoraria-BioAscent (Relationship has ended) | Advisor-Daiichi (Relationship has ended)



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Corey J. Langer, FACP

Advisor-Merck & Co | Grant or research support-Daiichi-Sankyo | Other: DSMC member-Oncocyte Dx | Other: DSMC Member-Summit Therapeutics | Advisor-Regeneron Pharmaceuticals, Inc. | Advisor-Astra Zeneca Pharmaceuticals | Consulting Fee-Gilead Sciences, Inc | Advisor-Genentech | Advisor-Amgen | Advisor-Mirati | Grant or research support-Guardant | Grant or research support-Navire (Relationship has ended) | Grant or research support-Fujifilm | Advisor-Novacure | Membership on Advisory Committees or Review Panels, Board Membership, etc.-RTOG Foundation | Advisor-Johnson & Johnson | Advisor-Pfizer, Inc. | Advisor-Eli Lilly

Tara C. Mitchell, MD

Honoraria-Merck & Co | Honoraria-Bristol-Myers Squibb | Honoraria-Pliant Therapeutics (Relationship has ended) | Honoraria-Pfizer (Relationship has ended) | Honoraria-GigaGen (Relationship has ended)

Keith W. Pratz, MD

Advisor-AbbVie, Inc. | Advisor-Bristol-Myers Squibb (Relationship has ended) | Advisor-Novartis / Amgen (Relationship has ended) | Advisor-Jazz Pharmaceuticals (Relationship has ended) | Advisor-Astellas (Relationship has ended) | Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) | Advisor-Roche (Relationship has ended)



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Edward A. Stadtmauer, MD

Grant or research support-AbbVie, Inc. | Consulting Fee-Glaxo Smith Kline (Relationship has ended) | Consulting Fee-Sanofi Genzyme (Relationship has ended) | Consulting Fee-Bristol-Myers Squibb (Relationship has ended) | Consulting Fee-Amgen (Relationship has ended)

Samuel U Takvorian, MD

Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) | Advisor-Genentech (Relationship has ended) | Grant or research support-Pfizer, Inc. (Relationship has ended) | Advisor-Exelixis (Relationship has ended)



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

**We Gratefully Acknowledge the Following Companies
for Providing Educational Grants**

Novartis

Varian Medical Systems

Thank you to Our Exhibitors

AbbVie

Acrotech Biopharma

ADC Therapeutics

Agios Pharmaceuticals

Amgen

Astellas, Oncology

Astellas, Precision Medicine

AstraZeneca (4 Tables)

Aveo Oncology

Bayer

Blueprint Medicines

Bristol Myers Squibb

Daiichi Sankyo, AML

Daiichi Sankyo, ADC Breast & Lung

Eisai

EMD Serono

Exact Sciences

Genentech

Genmab

Gilead Oncology

GSK

Guardant Health

Incyte

Iovance Biotherapeutics

Ipsen

Jazz Pharmaceuticals

Johnson & Johnson (2 Tables)

Karyopharm Therapeutics

Kite, A Gilead Company

Legend Biotech

Loxo@Lilly

Merck, Breast & Kidney



Penn Medicine
Abramson Cancer Center

UPDATES IN ONCOLOGY 2024

with Proceedings from International Medical Meetings

A CME/CNE-accredited Symposium

Thank you to Our Exhibitors

(continued)

Merck, Lung, GI & Bladder

Merck, Hematology

Mirati Therapeutics

Novartis, CAR-T

Novartis, Breast Oncology

Novartis, Hematology

Novartis, RLT Division

Pfizer, Breast Oncology

Pfizer, Oncology GU

Pfizer, Precision Medicine

PharmaEssentia

Puma Biotechnology

Regeneron

Sanofi

Secura Bio

Servier Pharmaceuticals

Sobi

Sumitomo Pharma

Syndax Pharmaceuticals

Taiho Oncology

Takeda, CRC Oncology

Takeda, Hematology Oncology